Aquestive Therapeutics, Inc. (AQST)

Nasdaq Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Financial Position (from SEC Filings)

$110.7M
Cash & Equivalents
$14.8M
Quarterly Burn Rate
22 mo
Est. Cash Runway
$502M
Market Cap

Estimated from most recent SEC quarterly filing. View SEC filings

Drug Pipeline (3 Assets)

DrugPhaseIndications
DIAZEPAM
LIBERVANT 		APPROVED —
ONDANSETRON
ZUPLENZ 		NDA Allergic Reaction, ALS, Amyotrophic Lateral Sclerosis, Epilepsy, Healthy, Healthy Participants, Nausea and Vomiting, Postoperative, Nausea With Vomiting Chemotherapy-Induced
RILUZOLE
EXSERVAN 		NDA —

Upcoming Catalysts

No upcoming catalysts detected for this company.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for AQST.

SEC EDGAR Filings

All SEC filings for Aquestive Therapeutics, Inc. on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.